These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 26565008)

  • 1. Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study.
    Orenstein R; Dubberke E; Hardi R; Ray A; Mullane K; Pardi DS; Ramesh MS;
    Clin Infect Dis; 2016 Mar; 62(5):596-602. PubMed ID: 26565008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
    Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P
    Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection.
    Youngster I; Russell GH; Pindar C; Ziv-Baran T; Sauk J; Hohmann EL
    JAMA; 2014 Nov; 312(17):1772-8. PubMed ID: 25322359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial.
    Orenstein R; Dubberke ER; Khanna S; Lee CH; Yoho D; Johnson S; Hecht G; DuPont HL; Gerding DN; Blount KF; Mische S; Harvey A
    BMC Infect Dis; 2022 Mar; 22(1):245. PubMed ID: 35279084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection: A Randomized Clinical Trial.
    Lee CH; Steiner T; Petrof EO; Smieja M; Roscoe D; Nematallah A; Weese JS; Collins S; Moayyedi P; Crowther M; Ropeleski MJ; Jayaratne P; Higgins D; Li Y; Rau NV; Kim PT
    JAMA; 2016 Jan; 315(2):142-9. PubMed ID: 26757463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660-A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection.
    Dubberke ER; Lee CH; Orenstein R; Khanna S; Hecht G; Gerding DN
    Clin Infect Dis; 2018 Sep; 67(8):1198-1204. PubMed ID: 29617739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral Vancomycin Followed by Fecal Transplantation Versus Tapering Oral Vancomycin Treatment for Recurrent Clostridium difficile Infection: An Open-Label, Randomized Controlled Trial.
    Hota SS; Sales V; Tomlinson G; Salpeter MJ; McGeer A; Coburn B; Guttman DS; Low DE; Poutanen SM
    Clin Infect Dis; 2017 Feb; 64(3):265-271. PubMed ID: 28011612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fecal microbiota transplant for recurrent Clostridium difficile infection: Mayo Clinic in Arizona experience.
    Patel NC; Griesbach CL; DiBaise JK; Orenstein R
    Mayo Clin Proc; 2013 Aug; 88(8):799-805. PubMed ID: 23910407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and preliminary efficacy of orally administered lyophilized fecal microbiota product compared with frozen product given by enema for recurrent Clostridium difficile infection: A randomized clinical trial.
    Jiang ZD; Jenq RR; Ajami NJ; Petrosino JF; Alexander AA; Ke S; Iqbal T; DuPont AW; Muldrew K; Shi Y; Peterson C; Do KA; DuPont HL
    PLoS One; 2018; 13(11):e0205064. PubMed ID: 30388112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term Follow-up Study of Fecal Microbiota Transplantation for Severe and/or Complicated Clostridium difficile Infection: A Multicenter Experience.
    Aroniadis OC; Brandt LJ; Greenberg A; Borody T; Kelly CR; Mellow M; Surawicz C; Cagle L; Neshatian L; Stollman N; Giovanelli A; Ray A; Smith R
    J Clin Gastroenterol; 2016; 50(5):398-402. PubMed ID: 26125460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful therapy of Clostridium difficile infection with fecal microbiota transplantation.
    Konturek PC; Koziel J; Dieterich W; Haziri D; Wirtz S; Glowczyk I; Konturek K; Neurath MF; Zopf Y
    J Physiol Pharmacol; 2016 Dec; 67(6):859-866. PubMed ID: 28195066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection.
    Brandt LJ; Aroniadis OC; Mellow M; Kanatzar A; Kelly C; Park T; Stollman N; Rohlke F; Surawicz C
    Am J Gastroenterol; 2012 Jul; 107(7):1079-87. PubMed ID: 22450732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does the donor matter? Donor vs patient effects in the outcome of a next-generation microbiota-based drug trial for recurrent Clostridium difficile infection.
    Ray A; Jones C
    Future Microbiol; 2016 May; 11():611-6. PubMed ID: 26986546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fecal microbiota transplantation for recurrent Clostridium difficile infection: Experience, protocol, and results.
    Reigadas E; Olmedo M; Valerio M; Vázquez-Cuesta S; Alcalá L; Marín M; Muñoz P; Bouza E
    Rev Esp Quimioter; 2018 Oct; 31(5):411-418. PubMed ID: 30221898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection in Patients With Cancer Treated With Cytotoxic Chemotherapy: A Single-Institution Retrospective Case Series.
    Hefazi M; Patnaik MM; Hogan WJ; Litzow MR; Pardi DS; Khanna S
    Mayo Clin Proc; 2017 Nov; 92(11):1617-1624. PubMed ID: 29101931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Long-term Efficacy and Safety of Fecal Microbiota Transplant for Recurrent, Severe, and Complicated Clostridium difficile Infection in 146 Elderly Individuals.
    Agrawal M; Aroniadis OC; Brandt LJ; Kelly C; Freeman S; Surawicz C; Broussard E; Stollman N; Giovanelli A; Smith B; Yen E; Trivedi A; Hubble L; Kao D; Borody T; Finlayson S; Ray A; Smith R
    J Clin Gastroenterol; 2016; 50(5):403-7. PubMed ID: 26352106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of Early Failure After Fecal Microbiota Transplantation for the Therapy of Clostridium Difficile Infection: A Multicenter Study.
    Fischer M; Kao D; Mehta SR; Martin T; Dimitry J; Keshteli AH; Cook GK; Phelps E; Sipe BW; Xu H; Kelly CR
    Am J Gastroenterol; 2016 Jul; 111(7):1024-31. PubMed ID: 27185076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients: methodology and results.
    Kelly CR; de Leon L; Jasutkar N
    J Clin Gastroenterol; 2012 Feb; 46(2):145-9. PubMed ID: 22157239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection.
    Dubberke ER; Orenstein R; Khanna S; Guthmueller B; Lee C
    Infect Dis Ther; 2023 Feb; 12(2):703-709. PubMed ID: 36544075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients.
    Webb BJ; Brunner A; Ford CD; Gazdik MA; Petersen FB; Hoda D
    Transpl Infect Dis; 2016 Aug; 18(4):628-33. PubMed ID: 27214585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.